- Home
- CRVO vs UNCY Comparison
CRVO vs UNCY Comparison
Compare CRVO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- UNCY
- Stock Information
- Founded
- CRVO 2001
- UNCY 2016
- Country
- CRVO United States
- UNCY United States
- Employees
- CRVO N/A
- UNCY N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- UNCY Health Care
- Exchange
- CRVO Nasdaq
- UNCY Nasdaq
- Market Cap
- CRVO 67.4M
- UNCY 74.2M
- IPO Year
- CRVO N/A
- UNCY 2021
- Fundamental
- Price
- CRVO $7.45
- UNCY $5.00
- Analyst Decision
- CRVO Strong Buy
- UNCY Strong Buy
- Analyst Count
- CRVO 6
- UNCY 5
- Target Price
- CRVO $19.17
- UNCY $55.20
- AVG Volume (30 Days)
- CRVO 109.4K
- UNCY 395.5K
- Earning Date
- CRVO 11-11-2025
- UNCY 11-12-2025
- Dividend Yield
- CRVO N/A
- UNCY N/A
- EPS Growth
- CRVO N/A
- UNCY N/A
- EPS
- CRVO N/A
- UNCY N/A
- Revenue
- CRVO $7,776,968.00
- UNCY N/A
- Revenue This Year
- CRVO N/A
- UNCY N/A
- Revenue Next Year
- CRVO N/A
- UNCY $19,912.34
- P/E Ratio
- CRVO N/A
- UNCY N/A
- Revenue Growth
- CRVO N/A
- UNCY N/A
- 52 Week Low
- CRVO $1.80
- UNCY $3.71
- 52 Week High
- CRVO $16.94
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- CRVO 38.31
- UNCY 64.95
- Support Level
- CRVO $7.03
- UNCY $4.69
- Resistance Level
- CRVO $8.38
- UNCY $5.34
- Average True Range (ATR)
- CRVO 0.54
- UNCY 0.32
- MACD
- CRVO -0.10
- UNCY 0.04
- Stochastic Oscillator
- CRVO 11.00
- UNCY 72.52
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.